Hims & Hers Shifts US Weight Loss Strategy, Partners with Novo Nordisk
Event summary
- Hims & Hers is collaborating with Novo Nordisk to align its US weight loss strategy with its global model.
- The company will now prioritize FDA-approved GLP-1 medications and offer compounded semaglutide on a limited basis.
- Hims & Hers will add Ozempic® and Wegovy® to its platform later this month, including various dosages and formulations.
- The agreement resolves a pending lawsuit between Hims & Hers and Novo Nordisk without prejudice.
The big picture
Hims & Hers' strategic pivot reflects the rapid evolution of the GLP-1 weight loss market, where branded medications have become increasingly accessible and affordable. This shift represents a move away from the company’s earlier reliance on compounded drugs and towards a more mainstream, FDA-approved model. The partnership with Novo Nordisk signals a consolidation of power within the weight loss space, potentially reshaping the competitive landscape and impacting smaller telehealth platforms.
What we're watching
- Customer Transition
- The success of Hims & Hers' strategy hinges on the ability to seamlessly transition existing compounded semaglutide users to branded FDA-approved medications, which could impact customer retention and platform engagement.
- Regulatory Scrutiny
- Increased reliance on branded GLP-1s may draw greater regulatory scrutiny towards Hims & Hers' platform and its role in facilitating access to these medications, potentially impacting operational costs and compliance requirements.
- Novo Nordisk Dependence
- Hims & Hers' future success is now heavily reliant on the ongoing partnership with Novo Nordisk, making it vulnerable to changes in Novo Nordisk's pricing, product availability, or strategic priorities.
Related topics